Good critical threads on Twitter. [MEDIA] [MEDIA]
They have 4 articles in total. Here are the other two: https://medicalnewsbulletin.com/the-me-cfs-myth/?amp=1...
[IMG]#MEAction Network UK @MEActNetUK Once you receive your gift card by email type in our name Myalgic Encephalomyelitis Action Network or EIN...
Ray Dalio and other celebrity friends are sponsoring $50 gift cards to the charity of your choice. Just input email here, and in about ten mins a...
It seems amazing.. Do you think this could mean anything for ME?
I voted yes.. I think it’s better to pay a nominal amount to each person than to have to pay a researcher to do the admin of reimbursement,...
Decades of research have not led to very effective disease modifying treatments for nearly all neurological diseases — eg ALS, Parkinson’s,...
[MEDIA]
Doesn’t look like it.
https://www.simmaronresearch.com/rapamycin-trial The First Biomarker-Driven Treatment Trial for ME/CFS Subsets Mean Success Until now, the...
Maybe..? I just looked at @Dakota15’s screenshots of their presentation and don’t see a reference to these numbers. I wonder if anyone who was...
[MEDIA] “Kaplan: only 40% noted worsening of energy after cardiovascular exercise, 20% reported mental fatigue, etc." What?? So 60% of the...
At the 14 minute mark makes some comments on the future of gene editing — that it will be used to turn up or down immune response by editing...
In an exclusive interview from his office at the Scripps Research Institute in La Jolla, CA, Dr. Topol discusses the latest on COVID, GLP-1s,...
I agree.. this to me is a total waste of funds. The anecdotal evidence is that neither work, despite doctors loving to claim the opposite.
Or maybe Nature.. it says 7 months on their site from submission to publication.. which would make it November.
I wish it didn’t sound so quacky.
Surprised to see someone say that people with ME have already accessed relvyrio — if that’s what he’s referring to.. [MEDIA]
Agree.. she was v well spoken.. she did a great job.
Separate names with a comma.
